Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed 31 Dec 2020.

Rutherford MJ, Lambert PC, Sweeting MJ, Pennington R, Crowther MJ, Abrams KR, et al. NICE DSU Technical Support Document 21. Flexible methods for survival analysis. 2020. http://nicedsu.org.uk/wp-content/uploads/2020/11/NICE-DSU-Flex-Surv-TSD-21_Final_alt_text.pdf. Accessed 31 Dec 2020.

Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Making. 2017;37(4):377–90.

Article  PubMed  Google Scholar 

Bullement A, Stevenson MD, Baio G, Shields GE, Latimer NR. A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Med Decis Making. 2023;2023:2729898.

Google Scholar 

Lambert PC, Smith LK, Jones DR, Botha JL. Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. Stat Med. 2005;24(24):3871–85.

Article  PubMed  Google Scholar 

Guyot P, Ades AE, Beasley M, Lueza B, Pignon JP, Welton NJ. Extrapolation of survival curves from cancer trials using external information. Med Decis Making. 2017;37(4):353–66.

Article  PubMed  Google Scholar 

Jackson-Christopher H. survextrap: a package for flexible and transparent survival extrapolation. BMC Med Res Methodol. 2023;23(1):282.

Article  CAS  PubMed  Google Scholar 

Vickers A. An Evaluation of survival curve extrapolation techniques using long-term observational cancer data. Med Decis Making. 2019;39(8):926–38.

Article  PubMed  PubMed Central  Google Scholar 

Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Penrod JR, Sharpe DJ, et al. Use of advanced flexible modeling approaches for survival extrapolation from early follow-up data in two nivolumab trials in advanced NSCLC with extended follow-up. Med Decis Making. 2023;43(1):91–109.

Article  CAS  PubMed  Google Scholar 

Lunn DJ, Thomas A, Best N, Spiegelhalter DJ. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37.

Article  Google Scholar 

Stan Development Team. RStan: the R interface to Stan. R package version 2.32.6. 2024. https://mc-stan.org/.

Stan Development Team. Stan reference manual. Version 2.35. 2024. https://mc-stan.org/docs/reference-manual/

Ades AE, Welton NJ, Caldwell D, Price M, Goubar A, Lu G. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy. 2008;13(Suppl 3):12–22.

Article  PubMed  Google Scholar 

R Core Team. R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. 1995. https://www.R-project.org/. Accessed 28 Oct 2022.

StataCorp. Stata statistical software. College Station: StataCorp LP. 1985.

SAS Institute Inc. SAS: SAS Institute Inc. 1972.

R for HTA. R for Health Technology Assessment (HTA). 2023. https://r-hta.org/. Accessed 27 Oct 2023.

National Institute for Health and Care Excellence (NICE). NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. 2014. https://www.nice.org.uk/guidance/ta319/. Accessed 31 Dec 2020.

National Institute for Health and Care Excellence (NICE). NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. 2018. https://www.nice.org.uk/guidance/ta531/. Accessed 27 Oct 2023.

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.

Article  CAS  PubMed  Google Scholar 

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.

Article  CAS  PubMed  Google Scholar 

Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, et al. 1127P—four-year survival update for metastatic melanoma (MM) patients (PTS) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study CA184-024. Ann Oncol. 2012;23:367.

Article  Google Scholar 

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718–32.

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armoiry X, Wang-Steverding X, Connock M, Grove A, Clarke A, Arun T, et al. Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis. Int J Technol Assess Health Care. 2022;38(1):e83.

Article  PubMed  Google Scholar 

Ayers D, Cope S, Towle K, Mojebi A, Marshall T, Dhanda D. Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/refractory multiple myeloma. BMC Med Res Methodol. 2022;22(1):272.

Article  PubMed  PubMed Central  Google Scholar 

Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019;19(1):182.

Article  PubMed  PubMed Central  Google Scholar 

Cooney P, White A. Direct incorporation of expert opinion into parametric survival models to inform survival extrapolation. Med Decis Making. 2023;43(3):325–36.

Article  PubMed  PubMed Central  Google Scholar 

Willigers BJA, Ouwens M, Briggs A, Heerspink HJL, Pollock C, Pecoits-Filho R, et al. The role of expert opinion in projecting long-term survival outcomes beyond the horizon of a clinical trial. Adv Ther. 2023;40(6):2741–51.

Article  PubMed  PubMed Central  Google Scholar 

Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. lancet Healthy longevity. 2022;3(10):e674–89.

Article  PubMed  Google Scholar 

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

Article  CAS  PubMed  Google Scholar 

Ibrahim JG, Chen MH, Gwon Y, Chen F. The power prior: theory and applications. Stat Med. 2015;34(28):3724–49.

Article  PubMed  PubMed Central  Google Scholar